<DOC>
	<DOCNO>NCT03038789</DOCNO>
	<brief_summary>This local , prospective , non-interventional , regulatory postmarketing surveillance study . Adult patient type 2 diabetes mellitus initiate Xigduo XR indicate Ministry Food Drug Safety ( MFDS ) include .</brief_summary>
	<brief_title>XIGDUO Extended Release ( XR ) ( DAPAGLIFLOZIN/METFORMIN XR FDC ) Regulatory Postmarketing Surveillance To Observe Safety Effectiveness Of XigduoXR ( Registered ) In Korean Patients</brief_title>
	<detailed_description>- Primary objective : Descriptive analysis proportion ( % ) adverse event ( AEs ) , serious adverse event ( SAEs ) , unexpected adverse events∙adverse drug reaction AEs special interest ( AESI ) patient treat Xigduo XR type 2 diabetes mellitus physician normal clinical practice set period 12 24 week . - Secondary objective : To follow change value hemoglobin A1c ( HbA1c ) , fast plasma glucose ( FPG ) , 2-hr post-prandial glucose ( PPG-2hr ) , blood pressure , abdominal circumference body weight self-reported data cohort patient baseline completion study . To evaluate safety tolerability Xigduo XR patient type 2 diabetes mellitus base conducted laboratory test ( Laboratory test mandatory non-interventional nature study )</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Patients enrol continuous registration method . Investigators enroll adult patient diagnose T2DM initiate treatment Xigduo XR first time . Patients ( legally acceptable representative ) inform pertinent aspect study sign Informed Consent Form use data . Discontinuation treatment determine patient 's willingness continue treatment investigator 's discretion . The reason discontinue treatment document . 1 . Patients age 18 year old 2 . Patients T2DM eligible treatment Xigduo XR first accord indication indicate locally approve prescribe information 3 . Patients evidence personally sign date informed consent document indicate patient ( legally acceptable representative ) inform pertinent aspect study . 1 . Hypersensitivity active substance excipients 2 . Patients renal impairment ( e.g. , serum creatinine level ≥ 1.5 mg/dL men , ≥ 1.4 mg/dL woman , creatinine clearance &lt; 60 milliliter ( mL ) /min estimate glomerular filtration rate ( eGFR ) &lt; 60mL/min/1.73 m2 ) may also result condition cardiovascular collapse ( shock ) , acute myocardial infarction , septicemia . 3 . Patients type 1 diabetes mellitus acute chronic metabolic acidosis include diabetic ketoacidosis without coma 4 . Congestive heart failure medicinal treatment require 5 . Patients radiologic study involve use intravascular iodinate contrast material ( example , intravenous urogram , intravenous cholangiography , angiography , compute tomography ( CT ) scan intravascular contrast material ) 6 . Patients severe infection severe traumatism 7 . In term Surgical procedure ( except minor procedure associate restrict intake food fluid ) 8 . Patients nutrition poor condition , starvation condition , pituitary insufficiency , capsular insufficiency 9 . Patients impaired hepatic function ( Since impair hepatic function associate case lactic acidosis , drug generally avoid patient clinical laboratory evidence hepatic disease . ) , respiratory failure , acute myocardial infarction , acute chronic disease cause histotoxic hypoxia like shock , alcoholic , gastroenteric trouble ( anhydremia , diarrhea , vomit etc . ) 10 . Pregnant woman , woman potential pregnancy , lactate woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>